ROS1‐G2032R, involving the substitution of glycine with arginine in the solvent front of ROS1 kinase domain, was found to mediate resistance to crizotinib and lorlatinib in ROS1 fusion‐positive NSCLC patients.83, 88. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.